查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600875

基因治療市場：按類型、載體類型、應用分類 - 2025-2030 年全球預測

Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年基因治療市值為56.7億美元，預計2024年將達70.5億美元，複合年成長率為27.15%，到2030年將達到304.8億美元。

基因療法是一種創新的醫學方法，旨在透過修改遺傳物質來治療或預防疾病，在對抗遺傳性疾病、某些癌症和病毒感染疾病方面具有巨大的潛力。這種需求源自於傳統治療方法的局限性，無法解決潛在的遺傳原因。應用包括罕見遺傳疾病的治療、癌症治療和血友病治療，顯著改善患者的治療效果。最終用途主要包括臨床研究、醫院和專科診所。

主要市場統計
基準年[2023] 56.7億美元
預測年份 [2024] 70.5億美元
預測年份 [2030] 304.8億美元
複合年成長率（%） 27.15%

由於基因工程的進步和研發投資的增加，基因治療市場正在經歷強勁成長。關鍵的成長要素包括監管支持、遺傳疾病盛行率的增加以及 CRISPR 等技術創新。此外，不斷成長的新型療法管道和市場參與企業之間的策略聯盟為業務擴張提供了潛在的機會。公司應專注於兒科適應症和新興市場，以利用未滿足的需求和政府獎勵。然而，限制因素包括高成本、道德問題、監管障礙和製造複雜性，這對擴充性和市場進入緩慢構成了挑戰。此外，長期安全性和有效性需要持續審查。

創新追求集中在改進遞送載體以提高精度和效率、開發個人化醫療方法以及利用人工智慧提高基因編輯精度和預測結果等領域。儘管市場正在快速發展，但由於全球監管和定價挑戰的不同，它仍然分散。公司可以透過投資合作研究來改進基因技術並擴大治療範圍來取得成功。嚴格的臨床試驗和夥伴關係的需要描繪了一幅需要堅韌和策略遠見的圖景。總體而言，專注於克服現有挑戰為公司提供了創新、最佳化成本和提高全球基因治療解決方案的可及性的機會。

市場動態：揭示快速發展的基因治療市場的關鍵市場洞察

供需的動態交互作用正在改變基因治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病流行和治療中心數量不斷增加
    • 政府對基因治療的支持與道德接受
  • 市場限制因素
    • 基因治療相關的高成本
  • 市場機會
    • 罕見疾病研發進展及基因治療進展
    • 創新的支付模式和有利的監管核准
  • 市場挑戰
    • 新基因療法的潛在副作用和道德擔憂

波特的五力策略工具駕馭基因治療市場

波特的五力架構是了解基因治療市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基因治療市場的外部影響

外部宏觀環境因素在塑造基因治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解基因治療市場的競爭狀況

對基因治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣基因治療市場供應商績效評估

FPNV定位矩陣是評估基因療法市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病盛行率上升，治療中心數量迅速增加
      • 政府對基因治療的治療和道德接受的支持
    • 抑制因素
      • 基因治療相關的高成本
    • 機會
      • 持續研究和開發罕見疾病和基因治療進展
      • 創新的支付模式和有利的監管核准
    • 任務
      • 新基因療法的潛在副作用和道德擔憂
  • 市場區隔分析
    • 類型： 癌症盛行率 癌症治療 基因治療
    • 載體類型：病毒載體的大量利用提高了基因遞送至細胞的效率
    • 應用：基因療法作為治療心血管疾病的創新方法的潛在應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 基因治療市場：依類型

  • 抗原基因治療
  • 癌症基因治療
  • 細胞激素基因治療
  • 自殺基因治療
  • 抑癌基因治療

第7章基因治療市場：依載體類型

  • 非病毒載體
  • 病毒載體

第8章基因治療市場：依應用分類

  • 心血管疾病
  • 遺傳疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤性疾病

第9章 北美和南美基因治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太基因治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的基因治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Charles River 宣布推出貸款平台以加速基於 LVV 的基因療法製造
    • Laurus 在印度推出基因治療資產
    • Bluebird Bio 準備推出基因療法作為鐮狀細胞疾病的應用方法

公司名單

  • Cellectis, Inc.
  • Novartis AG
  • Biogen Inc.
  • AnGes, Inc.
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Astellas Gene Therapies
  • Sarepta Therapeutics, Inc.
  • Uniqure NV
  • Applied Genetic Technologies Corporation
  • Mustang Bio
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Shenzhen SiBiono GeneTech Co. Ltd.
  • Spark Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Amgen Inc.
  • Sangamo Therapeutics, Inc.
  • AGC Biologics.
  • Merck & Co., Inc.
  • American Gene Technologies Inc.
  • Editas Medicine, Inc.
  • Bluebird Bio, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Human Stem Cells Institute
Product Code: MRR-437517DB6C62

The Gene Therapy Market was valued at USD 5.67 billion in 2023, expected to reach USD 7.05 billion in 2024, and is projected to grow at a CAGR of 27.15%, to USD 30.48 billion by 2030.

Gene therapy, a transformative medical approach aiming to treat or prevent diseases by modifying genetic material, holds immense potential in addressing inherited disorders, certain cancers, and viral infections. Its necessity arises from the limitation of traditional therapies unable to address root genetic causes. Applications include the treatment of rare genetic disorders, cancer therapy, and hemophilia, significantly enhancing patient outcomes. In terms of end-use, gene therapy primarily finds application in clinical research, hospitals, and specialty clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.67 billion
Estimated Year [2024] USD 7.05 billion
Forecast Year [2030] USD 30.48 billion
CAGR (%) 27.15%

The gene therapy market is experiencing robust growth, driven by advancements in genetic engineering and increased investment in research and development. Key growth factors include regulatory support, an increase in the prevalence of genetic diseases, and technological innovations like CRISPR. Additionally, the growing pipeline of novel therapies and strategic collaborations among market players present potential opportunities for expansion. Companies should focus on pediatric indications and emerging markets to leverage unmet needs and governmental incentives. However, limitations include high costs, ethical concerns, regulatory hurdles, and manufacturing complexities, which challenge scalability and delay market entry. Moreover, long-term safety and efficacy continue to be under scrutiny.

Innovative exploration can be concentrated in areas such as improving delivery vectors for better precision and efficiency, developing personalized medicine approaches, and utilizing AI for gene-editing precision and forecasting outcomes. The market features rapid advancements but remains fragmented due to varying global regulations and price-setting challenges. Businesses can thrive by investing in collaborative research to refine genetic technologies and expand therapeutic scopes. The necessity for rigorous clinical trials and partnerships depicts a landscape demanding persistence and strategic foresight. All in all, with a focus on overcoming existing challenges, businesses have the opportunity to innovate, optimize costs, and improve the accessibility of gene therapy solutions globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Therapy Market

The Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
    • Government Support and Ethical Acceptance of Gene Therapy For Treatments
  • Market Restraints
    • High Costs Associated with Gene Therapies
  • Market Opportunities
    • Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
    • Innovative Payment Models and Favorable Regulatory Approvals
  • Market Challenges
    • Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy

Porter's Five Forces: A Strategic Tool for Navigating the Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Therapy Market

A detailed market share analysis in the Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Cellectis, Inc., Novartis AG, Biogen Inc., AnGes, Inc., Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Astellas Gene Therapies, Sarepta Therapeutics, Inc., Uniqure N.V., Applied Genetic Technologies Corporation, Mustang Bio, Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Amgen Inc., Sangamo Therapeutics, Inc., AGC Biologics., Merck & Co., Inc., American Gene Technologies Inc., Editas Medicine, Inc., Bluebird Bio, Inc., Alnylam Pharmaceuticals, Inc., and Human Stem Cells Institute.

Market Segmentation & Coverage

This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy.
  • Based on Vector Type, market is studied across Non-viral Vectors and Viral Vectors.
  • Based on Application, market is studied across Cardiovascular Diseases, Genetic Diseases, Infectious Diseases, Neurological Diseases, and Oncological Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
      • 5.1.1.2. Government Support and Ethical Acceptance of Gene Therapy For Treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High Costs Associated with Gene Therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
      • 5.1.3.2. Innovative Payment Models and Favorable Regulatory Approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Prevalence of cancer gene therapy for cancer treatment
    • 5.2.2. Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells
    • 5.2.3. Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Gene Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Antigen Gene Therapy
  • 6.3. Cancer Gene Therapy
  • 6.4. Cytokine Gene Therapy
  • 6.5. Suicide Gene Therapy
  • 6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Non-viral Vectors
  • 7.3. Viral Vectors

8. Gene Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Genetic Diseases
  • 8.4. Infectious Diseases
  • 8.5. Neurological Diseases
  • 8.6. Oncological Disorders

9. Americas Gene Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
    • 12.3.2. Laurus to launch Gene Therapy Assets in India
    • 12.3.3. Bluebird bio Lays Gene Therapy Launch Groundwork As Sickle Cell Application Nears

Companies Mentioned

  • 1. Cellectis, Inc.
  • 2. Novartis AG
  • 3. Biogen Inc.
  • 4. AnGes, Inc.
  • 5. Orchard Therapeutics PLC
  • 6. Poseida Therapeutics, Inc.
  • 7. Astellas Gene Therapies
  • 8. Sarepta Therapeutics, Inc.
  • 9. Uniqure N.V.
  • 10. Applied Genetic Technologies Corporation
  • 11. Mustang Bio
  • 12. Abeona Therapeutics Inc.
  • 13. Adaptimmune Therapeutics PLC
  • 14. Shenzhen SiBiono GeneTech Co. Ltd.
  • 15. Spark Therapeutics, Inc.
  • 16. Ionis Pharmaceuticals, Inc.
  • 17. Amgen Inc.
  • 18. Sangamo Therapeutics, Inc.
  • 19. AGC Biologics.
  • 20. Merck & Co., Inc.
  • 21. American Gene Technologies Inc.
  • 22. Editas Medicine, Inc.
  • 23. Bluebird Bio, Inc.
  • 24. Alnylam Pharmaceuticals, Inc.
  • 25. Human Stem Cells Institute

LIST OF FIGURES

  • FIGURE 1. GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023